NRIX
Nurix Therapeutics, Inc.
$23.06
-1.63 (-6.60%)
At close · Jul 10
Market Cap
$2.39B
Shares
103,781,683
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$23.06
Open$24.86
Day$22.33–24.86
52W$8.20–25.09
Avg vol 30d2.9M
Short int17.8M · 17.1% float · 5.4d
Short vol78%
Last earningsJan 13, 2025
DataJul 2020–Jul 2026
Filing10-Q · Jul 9
Up next
FQ3-26 quarter ends
~Aug 30, 2026
Est
filed Jul 9, 2026
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+44%
above
Price vs 50-day avg
+26%
above
RSI (14)
65
neutral
MACD trend
Positive
52-week position
88%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+50%
trailing
6-month return
+22%
trailing
YTD return
+22%
this year
Relative strength
+13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $18 › 200d $16 — 50d above 200d
Institutional flow
Distributing
4 of 195 funds reported for Jun 30 · net -3.6K sh shares · +1 new
Insider flow
Distributing
Net -$743.9K over 90 days · 100% sells
Short interest
Falling
17.15% of float · ▼ -11.1% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
195 holders — near 3-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+99%
Y/Y
EPS growth
−6%
Y/Y
Free cash flow
$-263.5M
Balance sheet
$247.0M
net cash
Quant / Vol
risk profile
Volatility
63%
annualized · 1-yr
Max drawdown
−35%
past year
ATR
5.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+44%
Bullish
Price vs 50-day avg
+26%
Bullish
RSI (14)
65
Neutral
MACD trend
Positive
Bullish
52-week position
88%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $18 › 200d $16 — 50d above 200d
Institutional flow
Distributing
4 of 195 funds reported for Jun 30 · net -3.6K sh shares · +1 new
Insider flow
Distributing
Net -$743.9K over 90 days · 100% sells
Short interest
Falling
17.15% of float · ▼ -11.1% MoM · 5.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
195 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $8
Now $23 · 88%
52-wk high $25
vs 200-day avg +44%
vs 50-day avg +26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NRIX
this stock
Nurix Therapeutics, Inc.
|
$2.39B | +21.6% | +99.3% | — | 17.1% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NRIX | -3.8% | +50.1% | +22.3% | -5.0% | +21.6% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -5.2% | +46.1% | +13.2% | -6.1% | +10.9% |